Encouraging Trial Results for Hep C Drug Faldaprevir
Boehringer Ingelheim reports positive data from hepatitis drug trial
25 April 2013 11:01 in Pharmaceutical Company Product News
Boehringer Ingelheim has reported positive results from STARTVerso 1, a phase III trial evaluating the benefits of the new hepatitis C treatment faldaprevir.
Data from the study showed that the new once-daily protease inhibitor was able to deliver high viral cure rates and early therapy success among treatment-naive patients with genotype 1 hepatitis C infections.
Continue reading this entire article: